Mirum Pharmaceuticals (MIRM) Accumulated Expenses (2018 - 2026)

Mirum Pharmaceuticals' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $187.6 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 61.83% year-over-year to $187.6 million; the TTM figure through Mar 2026 stood at $187.6 million (up 61.83% YoY), while the FY2025 annual figure was $196.2 million, up 75.27% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $187.6 million, down from $196.2 million in the prior quarter.
• The five-year high for Accumulated Expenses was $196.2 million in Q4 2025, with the low at $6.8 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $89.6 million (2024), against an average of $87.3 million.
• Peak annual rise in Accumulated Expenses reached 784.6% in 2022, while the deepest fall reached 67.16% in 2022.
• Mirum Pharmaceuticals' Accumulated Expenses stood at $54.0 million in 2022, then jumped by 45.4% to $78.5 million in 2023, then jumped by 42.51% to $111.9 million in 2024, then surged by 75.27% to $196.2 million in 2025, then decreased by 4.36% to $187.6 million in 2026.
• Business Quant data shows MIRM's Accumulated Expenses at $187.6 million in Q1 2026, $196.2 million in Q4 2025, and $148.2 million in Q3 2025.